Antibody to stratum corneum (Antikeratin antibody) and antiperinuclear factor: Markers for progressive rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 26, Issue 5, 1997, Pages 346-349

  Kurki, P ^a,d   Von Essen, R ^b   Kaarela, K ^b   Isomaki H ^b   Palosuo, T ^c   Aho, K ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d Novartis Finland Oy   (Finland)

Author keywords

Antikeratin antibody; Antiperinuclear factor; Prognosis; Radiographic evaluation; Rheumatoid arthritis

Indexed keywords

ANTIPERINUCLEAR FACTOR; KERATIN ANTIBODY; RHEUMATOID FACTOR;

ARTICLE; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIOGRAPHY; RHEUMATOID ARTHRITIS; STRATUM CORNEUM;

EID: 0030780826     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749709065696     Document Type: Article

References (28)

1. Gabriel SE, Luthra HS. Rheumatoid arthritis: can the long-term outcome be altered? Mayo Clin Proc 1988;63:58-68.
2. Wolfe F. 50 years of antirheumatic therapy: the prognosis of rheumatoid arthritis. J Rheumatol 1990;17 (Suppl 22):24-32.
3. Van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and Physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
4. Willkens RF. Prognostic staging for therapy of rheumatoid arthritis. Semin Arthritis Rheum 1991;21 Suppl 1:40-3.
5. Wilke WS, Clough JD. Therapy for rheumatoid arthritis: Combinations of disease-modifying drugs and new paradigms of treatment. Semin Arthritis Rheum 1991;21 Suppl 1:21-34.
6. Emery P, Salmon M, Bradley H, Wordsworth P, Tunn E, Bacon PA, et al. Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. Br Med J 1992;305:1387-9.
7. Aho K, Heliövaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991;18:1282-4.
8. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32:97-103.
9. van Zeben D, Hazes JMW, Zwinderman AH, Cats A, van der Voort EAM, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992;51:1029-35.
10. Young BJJ, Mallya RK, Leslie RDG, Clark CJM, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979;ii:97-9.
11. Scott DL, Delamere JP, Jones LT, Wallon KW. The significance of laminar antikeratin antibodies to rat oesophagus in rheumatoid arthritis. Ann Rheum Dis 1981;40:217-71.
12. Cordonnier C, Meyer O, Palazzo E, De Bandt M, Elias A, Nicaise P, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996;35:620-4.
13. Kirstein H, Mathiesen FK. Antikeratin antibodies in rheumatoid arthritis. Scand J Rheumatol 1987;16:331-7.
14. von Essen R, Kurki P, Isomaki H, Okubo S, Kautiainen H, Aho K. Prospect for an additional laboratory criterion for rheumatoid arthritis. Scand J Rheumatol 1993;22:267-72.
15. Paimela L, Gripenberg M, Kurki P, Leirisalo-Repo M. antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 1992;51:743-6.
16. Kurki P, Aho K, Palosuo T, Heliövaara M. Immunopathology of rheumatoid arthritis: Antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992;35:914-7.
17. Hoet RMA, Boerbooms AMTh, Arends M, Ruiter DJ, van Venrooij WJ. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis 1991;50:611-8.
18. Sondag-Tschroots IRJM, Aaij C, Smit JW, Feltkamp TEW. The antiperinuclear factor. I. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Ann Rheum Dis 1979;38:248-51.
19. Marmont AM, Damasio EE, Bertorello C, Rossi F. Studies on the antiperinuclear factor. Arthritis Rheum 1967;10:117-28.
20. Youinou P, Serre G. The antiperinuclear factor and antikeratin antibody systems. Int Arch Allergy Immunol 1995;107:508-18.
21. Sebbag M, Simon M, Vincent C, Masson-Bessière L, Girbal E, Duriex J-J, et al. The antinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995;95:2672-9.
22. Berthelot JM, Maugars Y, Prost A, Youinou P. Rheumatoid arthritis and filaggrin. Rev Rhum Engl. Ed. 1995;62:127-38.
23. Nissilä M, Isomäki H, Kaarela K, Kiviniemi P, Martio J, Sarna S. Prognosis of inflammatory joint diseases. Scand J Rheumatol 1983;12:33-8.
24. Kaarela K. Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol 1985;14 Suppl 57:1-54.
25. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1976;18:481-91.
26. Tuomi T, Aho K, Palosuo T, et al. Significance of rheumatoid factors in an eight-year longitudinal study on arthritis. Rheumatol Int 1988;8:21-6.
27. Aho K, Tuomi T, Palosuo T, Kaarela K, von Essen R, Isomaki H. Is seropositive rheumatoid arthritis becoming less severe? Clin Exp Rheumatol 1989;7:287-90.
28. Kaarela K, Sarna S. Correlations between clinical facets of outcome in rheumatoid arthritis. Clin Exp Rheumatol 1993;11:643-4.